• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genetics of age-related macular degeneration: application to drug design.

作者信息

Chu Xi K, Tuo Jingsheng, Chan Chi-Chao

出版信息

Future Med Chem. 2013 Jan;5(1):13-5. doi: 10.4155/fmc.12.187.

DOI:10.4155/fmc.12.187
PMID:23256807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4148006/
Abstract
摘要

相似文献

1
Genetics of age-related macular degeneration: application to drug design.年龄相关性黄斑变性的遗传学：在药物设计中的应用
Future Med Chem. 2013 Jan;5(1):13-5. doi: 10.4155/fmc.12.187.
2
Can genetic factors predict response to antivascular endothelial growth factor therapy in age-related macular degeneration?遗传因素能否预测年龄相关性黄斑变性患者对抗血管内皮生长因子治疗的反应？
Can J Ophthalmol. 2011 Dec;46(6):549-51. doi: 10.1016/j.jcjo.2011.09.022.
3
Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration.年龄相关性黄斑变性对抗血管内皮生长因子治疗的耐药性。
Drug Des Devel Ther. 2013 Jun 17;7:485-90. doi: 10.2147/DDDT.S43470. Print 2013.
4
[Age-related macular degeneration: therapeutic hopes].[年龄相关性黄斑变性：治疗希望]
Med Sci (Paris). 2007 Feb;23(2):127-9. doi: 10.1051/medsci/2007232127.
5
Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.与湿性年龄相关性黄斑变性对血管内皮生长因子治疗反应相关的高危疾病位点的关联。
Retina. 2012 Jan;32(1):4-9. doi: 10.1097/IAE.0b013e31822a2c7c.
6
[Age-related macular degeneration and antivascular endothelial growth factor: a review].[年龄相关性黄斑变性与抗血管内皮生长因子：综述]
J Fr Ophtalmol. 2008 Jan;31(1):94-110. doi: 10.1016/s0181-5512(08)70342-5.
7
When should anti-vascular endothelial growth factor treatment be stopped in age-related macular degeneration?年龄相关性黄斑变性患者应在何时停止抗血管内皮生长因子治疗？
Am J Ophthalmol. 2010 Jan;149(1):4-6. doi: 10.1016/j.ajo.2009.08.039.
8
[Unspecific effects of certain siRNA molecules used in the treatment of age related macular degeneration].[用于治疗年龄相关性黄斑变性的某些小干扰RNA分子的非特异性作用]
Ugeskr Laeger. 2010 Sep 6;172(36):2457-9.
9
VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).VEGFA 和 VEGFR2 基因多态性与抗血管内皮生长因子治疗反应：年龄相关性黄斑变性治疗试验（CATT）比较。
JAMA Ophthalmol. 2014 May;132(5):521-7. doi: 10.1001/jamaophthalmol.2014.109.
10
[Age-related macular degeneration].年龄相关性黄斑变性
Nihon Rinsho. 2012 Nov;70 Suppl 8:647-51.

引用本文的文献

1
Another Round of "Clue" to Uncover the Mystery of Complex Traits.新一轮“线索”揭示复杂性状之谜。
Genes (Basel). 2018 Jan 25;9(2):61. doi: 10.3390/genes9020061.

本文引用的文献

1
Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis.年龄相关性黄斑变性（AMD）易感基因 CFH 中 Y402H 变异与 AMD 治疗反应的关系：一项荟萃分析。
PLoS One. 2012;7(8):e42464. doi: 10.1371/journal.pone.0042464. Epub 2012 Aug 14.
2
Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration.加载阶段、初始反应和 CFH 基因型对治疗新生血管性年龄相关性黄斑变性长期结局的影响。
PLoS One. 2012;7(7):e42014. doi: 10.1371/journal.pone.0042014. Epub 2012 Jul 25.
3
Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.CFH、ARMS2 和 VEGFA 风险等位基因累积效应对年龄相关性黄斑变性雷珠单抗治疗反应的影响。
Ophthalmology. 2012 Nov;119(11):2304-11. doi: 10.1016/j.ophtha.2012.05.040. Epub 2012 Jul 26.
4
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma.眼科药物发现：视网膜疾病和青光眼的新靶点和机制。
Nat Rev Drug Discov. 2012 Jun 15;11(7):541-59. doi: 10.1038/nrd3745.
5
Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).PF-04523655 与雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效评估（MONET 研究）。
Ophthalmology. 2012 Sep;119(9):1867-73. doi: 10.1016/j.ophtha.2012.03.043. Epub 2012 Jun 8.
6
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.VEGF 陷阱、雷珠单抗和贝伐珠单抗与血管内皮生长因子（VEGF）及其相关配体的结合和中和作用。
Angiogenesis. 2012 Jun;15(2):171-85. doi: 10.1007/s10456-011-9249-6.
7
5'-Adenosine monophosphate-activated protein kinase--mammalian target of rapamycin axis as therapeutic target for age-related macular degeneration.5'-腺嘌呤单核苷酸激活蛋白激酶 - 雷帕霉素哺乳动物靶点轴作为与年龄相关的黄斑变性的治疗靶点。
Rejuvenation Res. 2011 Dec;14(6):651-60. doi: 10.1089/rej.2011.1220. Epub 2011 Oct 18.
8
Macrophage polarization in the maculae of age-related macular degeneration: a pilot study.年龄相关性黄斑变性黄斑区巨噬细胞极化：一项初步研究。
Pathol Int. 2011 Sep;61(9):528-35. doi: 10.1111/j.1440-1827.2011.02695.x. Epub 2011 Aug 1.
9
Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration.补体成分 C5a 促进人 T 细胞表达白细胞介素-22 和白细胞介素-17 及其在年龄相关性黄斑变性中的作用。
J Transl Med. 2011 Jul 15;9:1-12. doi: 10.1186/1479-5876-9-111.
10
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性。
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.